Vertex Pharmaceuticals Incorporated (VRTX)

Vertex Pharmaceuticals Income Statement

Financials in millions USD. Fiscal year is January - December.

Year Ending	TTM	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Revenue	10,185	9,869	8,931	7,574	6,206	4,163
Revenue Growth (YoY)	10.61%	10.51%	17.91%	22.06%	49.08%	36.59%
Cost of Revenue	1,338	1,262	1,080	904.2	736.3	547.8
Gross Profit	8,847	8,607	7,850	6,670	5,469	3,615
Selling, General & Admin	1,238	1,137	944.7	840.1	770.5	658.5
Research & Development	3,209	3,163	2,540	1,938	1,645	1,755
Other Operating Expenses	256.8	527.1	115.5	1,113	184.6	0
Operating Expenses	4,704	4,827	3,601	3,891	2,600	2,413
Operating Income	4,143	3,780	4,250	2,779	2,869	1,202
Interest Expense / Income	43.1	44.1	54.8	61.5	58.2	58.5
Other Expense / Income	-667.8	-643.5	-37.3	-12.9	-305.7	-251.4
Pretax Income	4,767	4,380	4,232	2,730	3,117	1,395
Income Tax	748	760.2	910.4	388.3	405.2	218.1
Net Income	4,019	3,620	3,322	2,342	2,712	1,177
Net Income Growth	23.31%	8.96%	41.84%	-13.63%	130.43%	-43.88%
Shares Outstanding (Basic)	258	258	256	258	260	257
Shares Outstanding (Diluted)	261	261	259	260	263	261
Shares Change	0.31%	0.54%	-0.31%	-1.33%	1.04%	0.58%
EPS (Basic)	15.58	14.05	12.97	9.09	10.44	4.58
EPS (Diluted)	15.41	13.89	12.82	9.01	10.29	4.51
EPS Growth	22.79%	8.35%	42.29%	-12.44%	128.16%	-44.25%
Free Cash Flow	3,717	3,337	3,925	2,409	2,994	1,494
Free Cash Flow Per Share	14.40	12.95	15.33	9.35	11.52	5.82
Gross Margin	86.86%	87.21%	87.90%	88.06%	88.14%	86.84%
Operating Margin	40.67%	38.31%	47.59%	36.69%	46.24%	28.87%
Profit Margin	39.46%	36.68%	37.20%	30.92%	43.70%	28.27%
Free Cash Flow Margin	36.50%	33.81%	43.95%	31.80%	48.24%	35.89%
Effective Tax Rate	15.69%	17.36%	21.51%	14.22%	13.00%	15.64%
EBITDA	5,007	4,605	4,436	2,918	3,285	1,560
EBITDA Margin	49.16%	46.66%	49.67%	38.52%	52.93%	37.48%
Depreciation & Amortization	196	181.3	148.3	125.6	109.5	106.9
EBIT	4,811	4,424	4,287	2,792	3,175	1,453
EBIT Margin	47.23%	44.83%	48.01%	36.86%	51.16%	34.91%

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).